Stereotactic body radiation therapy as an effective and safe treatment for small hepatocellular carcinoma

Tao Zhang†, Jing Sun†, Weiping He, Huan Li, Junjie Piao, Huijun Xu and Xuezhang Duan*

Abstract

Background: To evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with small hepatocellular carcinoma (sHCC) who were ineligible for surgery or ablation therapies.

Methods: From March 2011 to December 2012, 28 cases with sHCC which were ineligible or refused surgical resection, transplantation or local ablation were treated with CyberKnife SBRT. Median size of tumors was 2.1 cm (range: 1.1–3.0 cm), a dose of 10–15Gy per fraction was given over 3–6 consecutive days, resulting in a total dose of 35–60Gy.

Results: The median follow-up period was 36 months, with the response rate of complete response (CR) in 17 cases, partial response (PR) in 8 cases, stable disease (SD) in 2 cases and progressive disease (PD) in one case. Overall response rate was 89.28%. Overall survival rates in 1, 2 and 3 years were 92.86, 85.71 and 78.57%, respectively. Local control rates in 1, 2 and 3 years were 96.43, 92.86 and 89.28%, respectively. No grade ≥3 hepatic toxicity was observed.

Conclusion: CyberKnife treatment was a safe and effective option for sHCC, which had shown good local control, high overall survival rates and low toxicity. CyberKnife SBRT could be served as an alternative treatment for patients with sHCC which is unsuitable for surgical treatment or local ablation.

Keywords: Hepatocellular carcinoma, Stereotactic body radiation therapy, CyberKnife, Efficacy, Safety

Background

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the fifth common malignant disease globally [1]. The annual diagnosis patients are over five hundred thousand [2]. According to the guideline, resection, liver transplantation and radiofrequency ablation (RFA) are the radical treatment options for small hepatocellular carcinoma (sHCC) [3]. However, only 10–30% patients who are diagnosed with sHCC are eligible for curative therapies due to several reasons [4]. Besides, for lack of donor and strict indications, liver transplantation is limited. RFA is the radical treatment option for the patients with sHCC. But if the tumor is close to bile duct or large vessels, or at deep location of the liver, or positioned at the top of the dome etc., the ablative therapy can’t be safely performed. The best treatment of sHCC remains controversial, particularly for sHCC patients who cannot be treated radically. Historically, the conventional radiotherapy for HCC has been limited due to the radiation sensitivity of normal liver, the risk of radiation-induced liver disease (RILD) after the whole liver radiation of low doses, and concern for the adjacent radiation sensitive organs such as stomach, duodenum, etc. [5]. In recent years, the advanced radiation therapy such as stereotactic body radiation therapy (SBRT) has shown high rates of local control for primary and metastatic liver cancers while avoids the risk of RILD. It is the best choice for sHCC patients who are unsuitable for resection, liver transplantation and RFA.

CyberKnife SBRT, which stands for the image guided precision radiation therapy, is the new type of stereotactic radiosurgery. The most important features of CyberKnife treatment are online position correction, respiratory synchronous tracking, real-time tracking and image guided radiotherapy, etc. Respiratory synchronous tracking system guides the accelerator to...
track the tumor movement, which can control the precision within 1 mm, realizing the precise therapy. Meanwhile, it enhances the dose of tumor region, reduces the dose of normal tissues nearby, and increases the therapeutic gain ratio. The aim of our study is to evaluate the curative effect and security of CyberKnife SBRT in treating sHCC in our hospital.

Methods

Patients enrollment

Between March 2011 and December 2012, 28 sHCC patients were treated with CyberKnife SBRT. All patients met the criteria as follows: (a) The max diameter of the tumors ≤3 cm; (b) Without portal vein tumor thrombus and lymphatic metastasis; (c) Without extrahepatic metastasis; (d) Unfeasible, difficult or refusing to undergo surgery or percutaneous ablative therapies; (e) Child-Pugh Classification (CPC) A or B; (f) eastern cooperative oncology group (ECOG) score 0 or 1; (g) Single tumor.

The clinical diagnosis was based on the result of imaging according to the international guidelines on the management of HCC [6]. The characteristic tumor appearance was defined by at least two imaging studies (including dynamic enhanced computed tomography (CT) and magnetic resonance imaging (MRI) scans as well as angiograms). All patients were managed in multidisciplinary setting with all legitimate treatment options available and provided with written informed consent before treatment.

Baseline characteristics of 28 patients were listed below (Table 1). Twenty-one men (75.0%) and 7 women (25.0%) were included in the study. The median age was 49 years old (22–65 years old). There were 24 hepatitis B patients (85.7%) and 4 hepatitis C patients (14.3%), in which there were 26 cirrhosis patients (92.86%). Alpha fetoprotein (AFP) level ranged from 1.3 ng/ml to 1000 ng/ml (median 19.3 ng/ml). Median tumor maximum diameter was 2.1 cm (range, 1.1 cm–3.0 cm). Ten patients (35.7%) had no previous treatment records and 18 patients (64.3%) were previously treated with procedures such as transcatheter arterial chemoembolization (TACE), RFA, etc. Among the 18 patients who had treatment history, 7 of them suffered recurrence within the liver outside the treated lesion, while the other 11 had incomplete responses after TACE, which were diagnosed by a characteristic tumor appearance by two imaging studies (including dynamic enhanced CT and MRI scans). Seasoned imaging doctors have provided assistance in diagnosis. Before enrollment, 19 hepatitis B patients had received antiviral treatment with entecavir or adefovir, and the serum HBV-DNA levels were all below 40 IU/ml. Another 5 hepatitis B patients, whose serum HBV-DNA levels showed positive, received antiviral treatment with entecavir after the enrollment. The 4 hepatitis C patients had also received antiviral treatment with peg-interferon and ribavirin before enrollment, and the serum HCV-RNA levels were all below 15 IU/ml.

| Variables                        | n (%) |
|---------------------------------|-------|
| Sex                             |       |
| Male                            | 21 (75.0) |
| Female                          | 7 (25.0)  |
| Age (years)                     |       |
| <60                             | 20 (71.4) |
| ≥60                             | 8 (28.6)  |
| Type of chronic hepatitis       |       |
| Hepatitis B                     | 24 (85.7) |
| Hepatitis C                     | 4 (14.3)  |
| Cirrhosis                       |       |
| Yes                             | 26 (92.9) |
| No                              | 2 (7.1)   |
| AFP (ng/ml)                     |       |
| <200                            | 22 (78.6) |
| ≥200                            | 6 (21.4)   |
| Child-Pugh classification       |       |
| A                               | 24 (85.7) |
| B                               | 4 (14.3)   |
| ECOG Score                      |       |
| 0                               | 25 (89.3) |
| 1                               | 3 (10.7)   |
| Tumor diameter (cm)             |       |
| ≤2 cm                           | 14 (50.0) |
| >2 cm, ≤3 cm                    | 14 (50.0) |
| Use of fiducials in SBRT        |       |
| Yes                             | 27 (96.4) |
| No                              | 1 (3.6)    |
| Previous treatments             |       |
| No                              | 10 (35.7) |
| Resection                       | 2 (7.1)    |
| TACE                            | 13 (46.4)  |
| Resection+TACE                  | 1 (3.6)    |
| TACE+RFA                        | 1 (3.6)    |
| TACE+PCA                        | 1 (3.6)    |

NOTE. Data presented as No (%)

Abbreviations: AFP alpha-fetoprotein, SBRT stereotactic body radiation therapy, TACE transarterial chemoembolization, RFA radiofrequency ablation, PCA percutaneous cryoablation
Cyberknife therapy
Fiducial implantation: 27 patients were implanted 3 to 5 fiducials 7 days prior to receiving CyberKnife treat-
ment. The fiducials were 6 cm from tumors in the
vicinity. The implantation of fiducials was to provide
target tracking during CyberKnife treatment. Twenty
seven patients with the implanted fiducials adopted
respiratory tracking and fiducial tracking techniques
simultaneously, while one patient adopted X-sight
spine tracking techniques.
CT localization: CT scan was undergone 1 week
after fiducial implantation. In addition to benchmark
image as plain CT scans, the auxiliary images were
chosen based on patients’ conditions, and these im-
ages are enhanced CT scans, MRI, positron emission
tomography-computed tomography(PET-CT) and hep-
atic arteriography, etc. The acquired parameters of
CT images are as follows: tilted angel of 0°; slice
thickness of 1 mm; voltage of 120 KV tube current of
400 mA; scan length of 20 cm; pixel size of 512 ×
512. The scan is head first with dorsal decubitus.
CyberKnife treatment plan design: Radiation thera-
pists delineated the gross target volume (GTV) and
organs at risk (normal liver, stomach, bowel, duode-
um, kidneys and spine cord). Planning target volume
(PTV) expands 3-5 mm of GTV. All plans were de-
signed by G4 CyberKnife MultiPlan (Version 4.0.2). A
total dose of 35-60Gy was delivered in 3–6 fractions.
The treatment plan enclosed PTV with 72–80% iso-
dose line of maximum dose quated to the prescribed
dose. In addition, normal tissues dose was within nor-
mal radiotherapy tolerance dose (TG-101 report).
CyberKnife treatment plan was transferred into treat-
ment control system. The treatment will be started
after data verification.

Post-therapy evaluation and follow-up
Follow-up period was defined from the last treatment
to patient’s loss or death. Follow-up was done every
3 months in the first year, then 3 or 6 months there-
after. A review of each patient’s prior medical history,
physical examination, complete blood counts, bio-
chemical profiles, tumor markers, liver function and
imaging examinations such as enhanced abdominal
CT scans or MRI were performed at each follow-up.
Short-term therapeutic evaluation was based on Modi-
fied Response Evaluation Criteria in Solid Tumors
(mRECIST) [7]. Complete response (CR) means all tar-
get tumor disappear in the enhanced CT images of ar-
terial phase; partial response (PR) means the diameter
sum of the target tumor reduces more than 30% in the
arterial phase enhancement CT images; progressive dis-
ease (PD) means the diameter sum of the target tumor
increases more than 20% in contrast CT images on the
arterial phase, or new tumor appears; stable disease (SD)
means reduced or increased volume between PR and
PD. Long-term therapeutic evaluation depended on
overall survival (OS) and local control (LC) at 1-year, 2-
year and 3-year, and LC rate indicates the proportion of
the patients with no tumor lesion progress. Toxicity re-
action evaluation was on the basis of the Common Ter-
nologo Criter for Adverse Events (CTCAE) version
4.0.J AM ACAD Dermatol [8].

Statistical analysis
SPSS 19.0 was used for statistical analysis. A P value
< 0.05 was defined as the threshold of statistical sig-
nificance. The overall survival and local control rates
were estimated using the Kaplan-Meier method. Fac-
tors significantly associated with OS and LC were
identified by multivariate analysis using a stepwise
Cox model, with calculation of hazard ratios (HRs)
and 95% confidence intervals (CIs).

Results
Short-term effect
All 28 patients completed the treatments. After 3–
6 months of SBRT, there were 17 patients with CR (60.71%),
8 patients with PR (28.57%), 2 patients with SD (7.14%)
and 1 patient with PD (3.58%). The response rate
was (CR + PR)/28 × 100% = 89.28%, and the disease con-
trol rate was (CR + PR + SD)/ 28 × 100% = 96.42%.

Long-term effect
The median follow-up was 36 months (3-53 months).
By October 2015, among the enrolled 28 patients, 6
patients died, in which 2 patients died of upper
gastrointestinal bleeding, 1 hepatic encephalopathy, 1
hepatorenal syndrome, 1 hepatic failure and 1 ob-
struction of biliary tract. The overall survival rates of
1-year, 2-year and 3-year were 92.86, 85.71 and 78.
57%, respectively. The local control rates of 1-year, 2-
year and 3-year were 96.43, 92.86 and 89.28%, re-
spectively (Fig. 1). An example of complete response
to SBRT assessed by MRI was showed below (Fig. 2).

Adverse events
All scheduled treatments were completed without man-
ifestations of toxicity. Acute toxicity reaction including
abdominal pain, fatigue, vomiting and anorexia could
be relieved gradually by symptomatic treatment. One
patient experienced grade 4 hyperbilirubinemia and
died of liver failure. However, the patient was classified
classified as CPC-A before the radiotherapy and the tumor
Diameter was only within 3 cm, so it is hard to distinguish liver failure caused by radiotherapy from that caused by other factors. Grade 1 aminopherase elevation was observed in 6 patients, and none of the patients have ALP elevation. After the symptomatic treatment, the laboratory test results returned to normal. The rest patients were with steady liver function during and after the therapy. Grade 1–2 hematotoxicity was manifested as thrombocytopenia and aleucocytosis. And Recombinanthuman granulocyte-colony stimulating factor (rhG-CSF) was prescribed to treat aleucocytosis. However, conservative method was applied to thrombocytopenia, and the platelet elevated gradually after the radiotherapy. None severe gastrointestinal complication happened, such as haemorrhage and perforation.

Clinical factors influencing OS and LC
To investigate the risk factors for overall survival rate and local control rate, clinical data, including sex, age, type of chronic hepatitis, cirrhosis, AFP, CPC and any other characteristics were analyzed. The results were all with no statistical significance (all P>0.05; Table 2). We also compared the overall survival rate, local control rate of two groups of patients, among which one group had previous treatment history while the other didn’t. The results showed no statistical significance (OS \( P = 0.774 \), LC \( P = 0.415 \)) as well.

Patients status after CyberKnife therapy
Thirteen patients were with tumor relapsed, among which 3 patients were infield, 9 patients were outfield, 1 patient was with metastasis to lung. The median recurrence time was 23.5 months (range, 6–52 months) after radiotherapy. Among the recurrent patients, 9 patients received TACE, 1 patient adopted RFA, 3 patients were retreated with CyberKnife SBRT.

Discussion
For patients with single lesion, especially sHCC, resection is the most effective treatment, with which the 5-year overall survival rate may run up to 60–70% [9, 10]. Sadly, merely a small part of the patients could receive the resection owing to the discompensated liver function, abnormal function of blood coagulation and the tumor positioning in the deep section of the liver, etc. [11]. Most patients cannot benefit from liver transplantation for the lack of donor and high expenses. For patients who are unsuitable for resection, percutaneous ablation therapy (RFA, anhydrous alcohol injection) are the radical procedures. The 5-year overall survival rate of sHCC patients with CPC-A who received RFA is same with the resection [12]. However, for tumors close to gallbladder, bile duct or large vessels, or near the diaphragm which is at the top of liver, the treatment is limited [13]. With the advancement of the radiation therapy, radiotherapy becomes one of the best choices for sHCC patients unsuitable for resection or RFA.

CyberKnife SBRT, featured with accurate high-dose radiotherapy, was first applied to recurrent squamous cell carcinoma of head and neck patients who have no resection options or not suitable for surgery [14]. Blomgren first applied SBRT to liver cancer patients with primary tumor or the secondary tumor who were unsuitable for surgery, TACE and RFA 20 years ago [15]. The results showed higher local control rate and lower toxicity reaction rate [16]. At present, HCC SBRT is the remedy radiotherapy for incomplete embolization of postoperative patients who
received TACE, transitional therapy of preoperative transplantation of liver and the option of recurrence HCC [17, 18].

Yoon SM and his coworkers reported 93 sHCC patients treated with SBRT, whose 1-year and 3-year OS was 86 and 53.8%, respectively, tumor diameter less than 6 cm, tumor number less than three, single fraction dose 10-20Gy, total doses 30-60Gy. They considered SBRT could be served as an alternative option for the patients unsuitable for other radical treatments.

Table 2 Multivariate analysis of risk factors for overall survival and local control

| Factor                   | Overall survival | Local control |
|--------------------------|------------------|---------------|
|                          | HR   | 95%CI       | P       | HR   | 95%CI       | P       |
| Sex                      | 0.689 | 0.061–7.771 | 0.763   | 0.725 | 0.160–3.296 | 0.678   |
| Age                      | 0.764 | 0.078–7.496 | 0.817   | 1.348 | 0.274–6.623 | 0.713   |
| Type of chronic hepatitis| 0.941 | 0.096–9.189 | 0.958   | 0.583 | 0.097–3.505 | 0.555   |
| Cirrhosis                | 0.075 | 0.004–1.275 | 0.073   | 0.767 | 0.054–10.915| 0.845   |
| AFP                      | 0.546 | 0.132–2.263 | 0.404   | 0.921 | 0.221–3.845 | 0.910   |
| Child                    | 0.080 | 0.003–2.250 | 0.138   | 0.636 | 0.067–6.053 | 0.694   |
| ECOG                     | 0.786 | 0.108–5.728 | 0.812   | 3.011 | 0.439–20.627| 0.262   |
| Tumor diameter (cm)      | 3.395 | 0.724–15.926| 0.121   | 1.218 | 0.308–4.825 | 0.778   |
| Previous treatments      | 1.209 | 0.404–3.620 | 0.734   | 0.796 | 0.301–2.104 | 0.645   |
In our research, the 1-year OS and 3-year OS were 92.86 and 78.57%, which were higher than the results above. We consider that with single dose of 10-15Gy and total doses of 35-60Gy, SBRT is an optional choice to treat shHCC patients whose diameter of tumor is less than 3 cm. Yuan Z retrospectively analyzed and compared the treatment effect of the CyberKnife SBRT and surgical resection of Barcelona stage I HCC patients. The result showed that the 1-year, 2-year and 3-year overall survival rates of the CyberKnife SBRT were 72.7, 66.7 and 57.1%, respectively, while the surgical resection were 88.5, 73.1 and 69.2% respectively. Numerically, the OS of resection was higher than radiotherapy. However, there were no statistical differences between them. The study showed equivalent curative effect between CyberKnife treatment and resection for the early-stage HCC patients [20]. Sylvain Dewas reviewed 120 patients who received CyberKnife treatment, among which 42 were HCC patients, 72 metastatic liver cancer; 6 cholangiocellular carcinoma. The median diameter was 33 mm, median GTV was 32.38cm³, and median total doses were 45Gy. The result indicated local control rates at 1-year and 2-year were 84 and 74.6%. In the meanwhile, total doses, tumor diameter and tumor volume were considered as the prognostic factors [21]. We analyzed clinical characteristics including sex, age, type of chronic hepatitis, etc., to discuss factors that may affect overall survival and local control rates. The analyzed results showed no statistical significance (Table 2). We supposed that this was caused by the small size of studied patients. We have conducted further studies by enrolling more patients to prove our conclusions.

Grade I and II hematotoxicity and hepatotoxicity were the main toxicity in our study, which was characterized with low-grade aminopherase elevation, bilirubin elevation, thrombocytopenia and anemia, and most of them could return to normal gradually after radiotherapy. Only one patient with hepatitis B liver cirrhosis suffered liver failure after 3 months of radiotherapy, who did not have liver enlargement, massive ascites and viral replication. For liver cirrhosis patients, the causes of liver function damage were complex and hard to figure out. Whereas for patients whose tumor was controlled well after radiotherapy and liver function failure wasn’t caused by tumor progress, they were more likely to suffer from serious liver injury with RILD. RILD was the major obstacles of HCC radiotherapy, and the incidence rate of liver radiotherapy was 5–10% when the dose of whole liver achieved 30-35Gy. The main inducing factors of RILD are the basic liver function, the liver cirrhosis and the PTV range [22]. Jung J predicted the RILD risk of SBRT on shHCC which cannot be resected according to dose-volume parameters, by which he discovered the risk for the cirrhosis patients with CPC-B suffering grade II hepatotoxicity was higher [23]. To evaluate liver function, indocyanine green test which is widely used in preoperation is more sensitive than CPC. However, CPC is much more important than indocyanine green test to forecast the risk of RILD [24].

Conclusion
CyberKnife SBRT is proved to be effective, with its main advantages being synchronous respiratory tracking, high dose delivery and low fraction [25]. Moreover, the treatment period is shorter. From the result of our study, CyberKnife SBRT was shown to be an effective and safety therapy for shHCC, which achieved higher local control rates, overall survival rates and lower toxicity reaction. The higher dose brought better local control rates but causing the risk of RILD. The optimal dose and hypofraction scheme are still controversial. Moreover, longer follow-up is required to evaluate the correlation between dose-response and potential late toxicity. SBRT achieved same effect with surgical operation. Our study had shown that nine of thirteen recurrent patients were outfielld recurrence, which was the main cause of recurrence. And CyberKnife SBRT may improve curative effect when combined with chemotherapy or targeted therapy.

Abbreviations
AFP: Alpha fetoprotein; CI: Confidence intervals; CPC: Child-Pugh classification; CR: Complete response; CT: computed tomography; CTCAE: Common Terminology Criteria for Adverse Events; ECOG: Eastern cooperative oncology group; GTV: Gross target volume; HCC: Hepatocellular carcinoma; HR: Hazard ratios; LC: Local control; mRECIST: Modified Response Evaluation Criteria in Solid Tumors; MRI: Magnetic resonance imaging; OS: Overall survival; P: P-value; PD: Progressive disease; PET-CT: Positron emission tomography-computed tomography; PR: Partial response; PTV: Planning target volume; RFA: Radiofrequency ablation; rG-CSF: Recombin- anthuman granulocyte-colony stimulating factor; RILD: Radiation-induced liver disease; SBRT: Stereotactic body radiation therapy; SD: Stable disease; TACE: Transcatheter arterial chemoembolization

Acknowledgements
We appreciate Dr. Jiuhong Chen (Accuray Medical Equipment Co.,Ltd.) for her valuable suggestions and editing support.

Funding
This study was supported by grants from Beijing Municipal Science and Technology Commission Fund (Z151100004015002) whose responsible person was Xuezhang Duan, who was responsible for the final approval of the version to be published.

Availability of data and materials
The information of the 28 patients involved in the study is presented in the following table.
Data sharing is not applicable to this article as no datasets were generated or analysed during the study.
TZ was involved in drafting the manuscript and revising it critically for important intellectual content; JS and HL made substantial contributions to acquisition of data; WH, HX and JP made substantial contributions to analysis and interpretation of data; XD was responsible for the final approval of the version to be published. Each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate
This study was approved by the Institutional Review Board of 302 Hospital of PLA (People’s Liberation Army) and was conducted in accordance with the Declaration of Helsinki and internationally accepted ethical guidelines. During their admission for SBRT treatment, the patients enrolled in this study provided written informed consent for their information to be stored in hospital databases and used for research.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 12 October 2017 Accepted: 11 April 2018 Published online: 20 April 2018

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–39.
3. Bruix J, Sherman M. American Association for the Study of liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.
4. Lau WW, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma—a strategy to increase resectability. Ann Surg Oncol. 2007;14(12):3301–9.
5. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31(5):1237–48.

| Number | Type of chronic hepatitis | Cirrhosis | Child-Pugh classification | ECOG Score | AFP (ng/ml) | Tumor diameter (cm) | Previous treatments | Total dose (Gy) |
|--------|--------------------------|-----------|---------------------------|------------|-------------|---------------------|-------------------|----------------|
| 1      | hepatitis B              | yes       | A5                        | 0          | 18.9        | 1.7                 | No                | 60             |
| 2      | hepatitis B              | yes       | A5                        | 0          | 16.5        | 1.6                 | No                | 60             |
| 3      | hepatitis B              | yes       | A6                        | 0          | 39          | 2.1                 | TACE              | 55             |
| 4      | hepatitis B              | yes       | A5                        | 1          | 484         | 2.1                 | TACE              | 54             |
| 5      | hepatitis B              | yes       | A5                        | 0          | 6.1         | 1.4                 | TACE              | 50             |
| 6      | hepatitis B              | yes       | A5                        | 0          | 203         | 2.4                 | TACE              | 54             |
| 7      | hepatitis B              | yes       | B8                        | 0          | 14.7        | 2.2                 | Resection         | 35             |
| 8      | hepatitis B              | yes       | A6                        | 0          | 193         | 2.9                 | No                | 54             |
| 9      | hepatitis B              | yes       | A5                        | 0          | 11.7        | 1.8                 | TACE+PCA          | 50             |
| 10     | hepatitis B              | yes       | A6                        | 1          | 10.5        | 2.8                 | No                | 55             |
| 11     | hepatitis B              | yes       | A5                        | 0          | 153         | 3                   | TACE              | 55             |
| 12     | hepatitis B              | yes       | B7                        | 0          | 12.3        | 2.1                 | TACE+RFA          | 49             |
| 13     | hepatitis B              | yes       | A6                        | 0          | 249         | 2.9                 | No                | 54             |
| 14     | hepatitis B              | yes       | A5                        | 0          | 5           | 1.2                 | TACE              | 50             |
| 15     | hepatitis C              | no        | A5                        | 0          | 7           | 2.8                 | Resect+TACE       | 60             |
| 16     | hepatitis C              | yes       | B7                        | 0          | 22.7        | 2.7                 | TACE              | 49             |
| 17     | hepatitis B              | yes       | A5                        | 0          | 56          | 2                   | TACE              | 54             |
| 18     | hepatitis B              | yes       | A6                        | 0          | 109         | 1.5                 | TACE              | 55             |
| 19     | hepatitis C              | yes       | A6                        | 0          | 22          | 1.5                 | TACE              | 50             |
| 20     | hepatitis B              | yes       | A5                        | 0          | 447         | 2.2                 | TACE              | 55             |
| 21     | hepatitis B              | yes       | A6                        | 0          | 4.03        | 3                   | No                | 50             |
| 22     | hepatitis B              | yes       | A5                        | 1          | 2.38        | 1.4                 | No                | 55             |
| 23     | hepatitis B              | yes       | A5                        | 0          | 1.3         | 1.6                 | No                | 54             |
| 24     | hepatitis B              | yes       | A6                        | 0          | 1000        | 1.1                 | TACE              | 60             |
| 25     | hepatitis C              | yes       | B7                        | 0          | 47          | 1.8                 | TACE              | 49             |
| 26     | hepatitis B              | yes       | A5                        | 0          | 12          | 1.6                 | No                | 55             |
| 27     | hepatitis B              | no        | A5                        | 0          | 41.66       | 2.1                 | Resection         | 54             |
| 28     | hepatitis B              | yes       | A5                        | 0          | 247         | 1.9                 | No                | 55             |

Note: of 28 patients involved in the study, 7 are female and 21 male; 8 are 60 years old or beyond while the other 20 are below 60
6. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.

7. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.

8. Chen AP, Setser A, Anadkat MJ, Cottilar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol. 2012;67(5):1025–39.

9. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5(3):215–9.

10. Bruix J, Sherman M. Practice guidelines committee AASLD. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.

11. Rahbari NN, Mehbabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253(3):453–69.

12. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52(2):762–73.

13. Decadt B, Srinvaradna AK. Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol. 2004;5(9):550–60.

14. Comet B, Kramar A, Faivre-Pierret M, Dewas S, Coche-Dequeant B, Degardin M, et al. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2012;84(1):203–9.

15. Blommers H, Laa I, Nielund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34(6):861–70.

16. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2013;87(1):22–32.

17. Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2017;27(3):247–55.

18. Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, et al. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol. 2017;12(1):116.

19. Yoon SM, Lim YS, Park MJ, Kim SY, Cho B, Shin JH, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One. 2013;8(11):e79854.

20. Yuan Z, Tian L, Wang P, et al. Comparative research on the efficacy of cyberknife and surgical excision for stage heptacellular carcinoma. Onco Targets Ther. 2013;6:1527–32.

21. Dewas S, Billaute JF, Mirabel X, Fumagalli I, Kramar A, Jarzaya H, et al. Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol. 2012;7:166.

22. Cheng KC, Wu JK, Huang CM, Liu HS, Huang DY, Cheng SH, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys. 2002;54(1):156–62.

23. Jung J, Yoon SM, Kim SY, Cho B, Park JH, Kim SS, et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol. 2013;8:249.

24. Lee U, Seong J, Shim SJ, Han KH. Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73(1):154–8.

25. Martin A, Gay A. Stereotactic body radiotherapy: a review. Clin Oncol. 2010;22(3):157–72.